What Is DEL Technology?
DELs (DNA-encoded chemical libraries) are collections of small molecules that are synthetically produced and chemically modified to attach to DNA segments. DNA acts as a code to track and identify individual molecules in the library. By encoding a single molecule with DNA, hundreds of millions of unique compounds can be stored in a library, allowing high-throughput screening of potential drug molecules for drug discovery and development. This technology rapidly speeds up the drug discovery process by enabling large-scale screening of different compounds.
An overview of DNA-encoded chemical libraries. 
What We Do for DELs
At Alfa Chemistry, we use the latest synthetic chemistry technology and automated synthesis platform to construct the expected DELs, and provide one-stop service for DEL synthesis and DEL screening.
- Construction And Synthesis of DELs
The construction of DELs involves the synthesis of large numbers of individual compounds, each of which is then linked to a unique DNA identifier. Based on tens of thousands of high-quality molecular building blocks with diverse structures, Alfa Chemistry has the excellent ability to construct DELs with diverse chemical spaces, novel structures, and billions of compounds.
Schematic representation of DNA-encoded chemical libraries. 
- Screening of DELs
Compared to conventional HTS, DEL technology offers the possibility to screen billions of molecules in a single experiment. Available screening methods include solid-phase affinity-based screening (such as magnetic beads and resin-filled tips), interaction-dependent PCR, and DNA photoaffinity labeling (DPAL).
DEL solid phase screening process:
Choose Alfa Chemistry
With our unparalleled expertise and commitment to quality, Alfa Chemistry is poised to help drive the next wave of innovation in drug discovery through our DEL construction and synthesis services. To get started with our services, or to discuss our capabilities with a member of our expert team, contact us today.
- Adrián Gironda-Martínez, et al. ACS Pharmacol. Transl. Sci., 2021, 4, 4, 1265-1279.
- Nicholas Favalli, et al. FEBS Lett., 2018, 592, 2168-2180.